14 Feb 2026
Patient selection for tricuspid TEER in 2026
Anchorperson:
S. Kuwata
Spokesperson:
A. Lee
Summary
This session delineates criteria for optimal patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. Integrating anatomical, haemodynamic, and clinical parameters, it clarifies the evolving indications relative to transcatheter tricuspid valve replacement (TTVR) and conservative management. Real-world cases informed by pivotal trials such as TRILUMINATE, TRISCEND-II, and CLASP TR illustrate practical application and management of complex scenarios.
Learning Objectives
- To identify optimal candidates for tricuspid TEER in contemporary practice
- To integrate anatomical, haemodynamic, and clinical criteria into patient selection
- To understand the evolving boundaries between TEER, TTVR, and conservative management
- To apply lessons from current evidence (TRILUMINATE Pivotal, TRISCEND-II, CLASP TR, etc.) to real-world cases